236 related articles for article (PubMed ID: 30746706)
1. Molecular comparison of interval and screen-detected breast cancers.
Cheasley D; Li N; Rowley SM; Elder K; Mann GB; Loi S; Savas P; Goode DL; Kader T; Zethoven M; Semple T; Fox SB; Pang JM; Byrne D; Devereux L; Nickson C; Procopio P; Lee G; Hughes S; Saunders H; Fujihara KM; Kuykhoven K; Connaughton J; James PA; Gorringe KL; Campbell IG
J Pathol; 2019 Jun; 248(2):243-252. PubMed ID: 30746706
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of screen-detected breast cancer.
Farshid G; Walters D
Breast Cancer Res Treat; 2018 Nov; 172(1):191-199. PubMed ID: 30046938
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
4. Genetic landscape of interval and screen detected breast cancer.
Mills C; Sud A; Everall A; Chubb D; Lawrence SED; Kinnersley B; Cornish AJ; Bentham R; Houlston RS
NPJ Precis Oncol; 2024 May; 8(1):122. PubMed ID: 38806682
[TBL] [Abstract][Full Text] [Related]
5. PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.
Puvanesarajah S; Nyante SJ; Kuzmiak CM; Chen M; Tse CK; Sun X; Allott EH; Kirk EL; Carey LA; Perou CM; Olshan AF; Henderson LM; Troester MA
Cancer Prev Res (Phila); 2018 Jun; 11(6):327-336. PubMed ID: 29622545
[TBL] [Abstract][Full Text] [Related]
6. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and tumor characteristics of interval cancers by mammographic density.
Holm J; Humphreys K; Li J; Ploner A; Cheddad A; Eriksson M; Törnberg S; Hall P; Czene K
J Clin Oncol; 2015 Mar; 33(9):1030-7. PubMed ID: 25646195
[TBL] [Abstract][Full Text] [Related]
8. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of germline variants in inflammatory breast cancer.
Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
Phi XA; Houssami N; Hooning MJ; Riedl CC; Leach MO; Sardanelli F; Warner E; Trop I; Saadatmand S; Tilanus-Linthorst MMA; Helbich TH; van den Heuvel ER; de Koning HJ; Obdeijn IM; de Bock GH
Eur J Cancer; 2017 Nov; 85():31-38. PubMed ID: 28886475
[TBL] [Abstract][Full Text] [Related]
11. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
12. Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes.
Li J; Ivansson E; Klevebring D; Tobin NP; Lindström LS; Holm J; Prochazka G; Cristando C; Palmgren J; Törnberg S; Humphreys K; Hartman J; Frisell J; Rantalainen M; Lindberg J; Hall P; Bergh J; Grönberg H; Czene K
Clin Cancer Res; 2017 May; 23(10):2584-2592. PubMed ID: 27587435
[No Abstract] [Full Text] [Related]
13. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.
Kirsh VA; Chiarelli AM; Edwards SA; O'Malley FP; Shumak RS; Yaffe MJ; Boyd NF
J Natl Cancer Inst; 2011 Jun; 103(12):942-50. PubMed ID: 21540443
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
15. Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.
Walbaum B; Puschel K; Medina L; Merino T; Camus M; Razmilic D; Navarro ME; Dominguez F; Cordova-Delgado M; Pinto MP; Acevedo F; Sánchez C
Breast Cancer Res Treat; 2021 Sep; 189(2):561-569. PubMed ID: 34244869
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers.
Niraula S; Biswanger N; Hu P; Lambert P; Decker K
JAMA Netw Open; 2020 Sep; 3(9):e2018179. PubMed ID: 32975573
[TBL] [Abstract][Full Text] [Related]
17. Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.
Chuang SL; Chen SL; Yu CP; Chang KJ; Yen AM; Chiu SY; Fann JC; Tabár L; Stephen DW; Smith RA; Chen HH
APMIS; 2014 Aug; 122(8):699-707. PubMed ID: 25046200
[TBL] [Abstract][Full Text] [Related]
18. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
[TBL] [Abstract][Full Text] [Related]
19. Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Cortesi L; Canossi B; Battista R; Pecchi A; Drago A; Dal Molin C; Toss A; De Matteis E; Marchi I; Torricelli P; Cascinu S
Int J Cancer; 2019 Mar; 144(5):1001-1009. PubMed ID: 30098212
[TBL] [Abstract][Full Text] [Related]
20. Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?
de Munck L; Siesling S; Bart J; Menke-Pluijmers MB; Otter R; Willemse PH
Eur J Cancer Prev; 2013 Sep; 22(5):398-403. PubMed ID: 23492953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
